Curcumin Supplement in Nonalcoholic Fatty Liver Patients

National Nutrition and Food Technology Institute

Status and phase

Completed

Phase 3

Phase 2

Conditions

Nonalcoholic Fatty Liver

Type 2 Diabetes

Treatments

Dietary Supplement: placebo

Dietary Supplement: curcumin

Study type

Interventional

Funder types

Other

Identifiers

NCT02908152

467

Details and patient eligibility

About

The purpose of this study is to investigate the effects of curcumin supplement on metabolic factors and hepatic fibrosis in nonalcoholic fatty liver patients with type 2 diabetes. Subjects will participate in 3 month, two group, randomized intervention, where one group (n=25) will take 1.5g/d curcumin and the other group (n=25) will take a placebo to compare differences in outcomes between the two groups.

Enrollment

50 patients

Sex

All

Ages

30 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patient diagnosed with type 2 diabetes based on ADA definition or who only take oral antidiabetic drug;
CAP score >263.

Exclusion criteria

Taking any kind of antibiotics two weeks before recruitment;
History of alcohol consumption;
pregnancy or lactation;
Professional athletes;
Other liver disease (viral/etc);
High dose synthetic estrogens, methotrexate, amiodarone, steroids, chloroquine, immunosuppressive drugs;
A history of Cardiovascular disease;
Renal disease, Celiac disease, Cirrhosis;
History of Upper GI surgery;
A history of hypothyroidism or Cushing's syndrome;
History of drug dependence;
Body mass index (BMI) ≥35 kg/m2;
A restrictive diet or weight change ≥ 5 kg during the 3months prior to study;
Any change in treatment with oral hypoglycemic; anti hypertensive and antilipid agents during the study;
Use of weight loss medications.